Charles Schwab Investment Management Inc. Has $912,000 Stock Holdings in Rapport Therapeutics, Inc. $RAPP

Charles Schwab Investment Management Inc. lifted its stake in Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) by 23.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 90,968 shares of the company's stock after purchasing an additional 17,459 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.25% of Rapport Therapeutics worth $912,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in RAPP. Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics during the fourth quarter worth $41,000. Wells Fargo & Company MN increased its stake in Rapport Therapeutics by 38.9% during the fourth quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock valued at $86,000 after purchasing an additional 1,352 shares during the last quarter. Catalyst Private Wealth LLC bought a new stake in Rapport Therapeutics during the first quarter valued at $100,000. JPMorgan Chase & Co. grew its position in shares of Rapport Therapeutics by 77.8% during the fourth quarter. JPMorgan Chase & Co. now owns 7,170 shares of the company's stock worth $127,000 after acquiring an additional 3,137 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Rapport Therapeutics by 40.1% during the first quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock worth $144,000 after acquiring an additional 4,109 shares during the last quarter.

Insider Buying and Selling at Rapport Therapeutics

In related news, insider David Bredt sold 8,500 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $15.00, for a total value of $127,500.00. Following the transaction, the insider owned 426,642 shares in the company, valued at $6,399,630. This trade represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 25,500 shares of company stock valued at $365,500 in the last three months. Company insiders own 13.57% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Rapport Therapeutics in a report on Wednesday, August 6th. They issued a "buy" rating and a $31.00 price objective for the company. JMP Securities reissued a "market outperform" rating and issued a $28.00 price target on shares of Rapport Therapeutics in a report on Tuesday, July 8th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $29.50.

Rapport Therapeutics Trading Down 6.4%

Rapport Therapeutics stock traded down $0.99 during trading hours on Friday, reaching $14.36. 371,868 shares of the company were exchanged, compared to its average volume of 193,788. Rapport Therapeutics, Inc. has a 12 month low of $6.43 and a 12 month high of $29.74. The firm has a market cap of $524.14 million, a price-to-earnings ratio of -5.74 and a beta of 0.73. The stock has a 50-day moving average of $14.62 and a 200 day moving average of $11.92.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.12. As a group, research analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.